Jb Chemicals & Pharmaceuticals Ltd. · NSE:JBCHEPHARM
Jb Chemicals & Pharmaceuticals — Q2 FY26 Earnings Presentation
30 slides from Jb Chemicals & Pharmaceuticals's earnings presentation, Nov 11, 2025
Slide 1: Company Presentation cover letter to NSE
November 11, 2025 National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No. C/1, G-Block, Bandra Kurla Complex, Bandra (E), Mumbai – 400051. Stock Symbol: JBCHEPHARM Dear Sir, Sub: Company Presentation Enclosed is Company’s presentation on financial results for the quarter ended o
Slide 2: JB Pharma – Q2 FY26 & H1 FY26 Investor Presentation
JB Pharma – Q2 FY26 & H1 FY26 Investor Presentation November 11, 2025 www.jbpharma.com jbpharma/
Slide 3: Disclaimer
Disclaimer No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the d
Slide 4: JB Pharma – Looking ahead
> Synergistic acquisitions 5.) productivity Domestic outperformer @® g Gl leader A . Strong FCF GOOD PEOPLE 5 Consistency of delivery 9 for C000 HEATH _ Dosage ols op Global regulatory approvals Medicated/Herbal lozenges a p : a Leadership Key therapies Pillar Brands “J B PHARMA ** Dosage forms Stat
Slide 5: Top 5 brands, 40+ years of operations
49 6 40+ Top 5 Brands among top 300 brands Regulated/semi-regulated Global manufacturer of Years of operations with (IQVIA MAT Sep’25 data), markets of presence through medicated/herbal lozenges consistent track record across contributing over 50% of direct operations and representing a substantial
Slide 6: Corporate Snapshot – Financial Overview
Corporate Snapshot – Financial Overview Revenue (INR cr) PAT (INR cr) ^Op EBITDA Margin (%) ROE (%) ROCE (%) 27.4% 27.0% 27.7% 42% 25.0% 24.3% 3,918 21.3% 32% 3,484 18.6% 3,149 29% 27% 15.4% 24% 2,424 22% # 21% 2,043 1,643 1,775 15% 25% 1,413 19% 18% 19% 19% 17% 553 660 449 386 410 13% 139 194 272 1
Slide 7: World Class Manufacturing Facilities
World Class Manufacturing Facilities 8 25+ 10 State of the Art Global Dosage forms manufacturing Regulatory produced facilities Accreditations Tablets Capsules Liquids IV Infusions Ampules Vials Ointments Cold Rubs Lozenges Sips 6
Slide 8: Q2 FY26 Business Performance
Q2 FY26 Business Performance
Slide 9: CEO's Message
CEO’s Message “ “JB’s domestic business continued to outperform the market, with all major brands delivering robust growth. Our focus on driving steady volume growth across key brands — including recently acquired portfolios — continues to yield good results. On the international front, momentum in
Slide 10: Results Overview: Q2 FY26 vs Q2 FY25
Results Overview: Q2 FY26 vs Q2 FY25 Revenues (INR crores) 9% o JB Pharma’s revenue grew 8% to INR 1085 crores vs INR 1001 crores 8% 2,179 2,005 o Domestic formulations business recorded revenue of 1,001 1,085 INR 644 crores vs INR 588 crores (YoY growth of 9%) • The chronic as well as the acute seg
Slide 11: EBITDA Analysis – Q2 FY26
EBITDA Analysis – Q2 FY26 INR crores Q2 FY26 Q2 FY25 H1 FY26 H1 FY25 Revenue 1085 1001 2179 2005 Reported EBITDA 310 271 611 551 Non Cash ESOP Charge 9 14 23 25 Included in Employee Benefits expense One off charges on account of the One-off charge - - 15 - proposed merger scheme Operating EBITDA (ex
Slide 12: Financial Overview Q2 FY26 vs Q2 FY25
Financial Overview Q2 FY26 vs Q2 FY25 Op. EBITDA (INR crores) 29.8% 28.7% 649 o Operating EBITDA grew by 12% to INR 319 crores vs INR 285 576 crores 29.4% o Operating EBITDA margin was at 29.4% vs 28.4% 28.4% 319 13% o Operating EBITDA margin for H1 FY26 was 29.8% vs 28.7% 285 for H1 FY25 o Gross ma
Slide 13: JB Balance Sheet: Cash flows remain strong
JB Balance Sheet : Cash flows remain strong As on 30 As on 31 Balance Sheet (INR Cr) Sept’25 Mar’25 o Operating cash flows in H1 FY26 were INR 363 crores vs Net Worth 3806 3433 INR 378 crores in H1 FY25 • Cash tax increased to INR 116 crores in H1 FY26 vs Other Liabilities 490 416 97 crores in H1 FY
Slide 14: Domestic Business Q2 FY26
Domestic Business Q2 FY26 Domestic Formulations (INR crores) o Domestic business continued its momentum and registered YoY growth of 9% to INR 644 crores 12% o Domestic business constitutes 61% of overall turnover in H1 FY26 as compared to 59% of revenue in H1 FY25 1322 o JB Pharma continues to rema
Slide 15: JB continues as one of the fastest growing companies
JB continues as one of the fastest growing companies, maintaining a market beating performance Among top 25, JB is one of the Among the Fastest growing fastest growing pharma Leadership position company as per IQVIA MAT company in the IPM in the covered markets Sept’25 data 12% Vs IPM growth 35% + s
Slide 16: 6 Brands now rank among the Top 300 in the IPM
6 Brands now rank among the Top 300 in the IPM MAT Sept’22 Value Sales* MAT Sept’25 Value Sales* MAT Sept’22 Rank MAT Sept’25 Rank CILACAR 292 490 #48 #22 RANTAC 314 347 #41 #50 CILACAR-T 122 252 #212 #100 METROGYL 173 236 #149 #113 NICARDIA 120 210 #218 #144 SPORLAC 78 129 #385 #266 15 All data as
Slide 17: Building Stronger Brand Franchises
Building Stronger Brand Franchises INR 466 crs INR 851 crs INR 375 crs INR 418 crs INR 248 crs INR 328 crs IQVIA MAT Sept’22 IQVIA MAT Sept’25 IQVIA MAT Sept’22 IQVIA MAT Sept’25 IQVIA MAT Sept’22 IQVIA MAT Sept’25 CILACAR T RANTAC DOM METROGYL P CILACAR M RANTAC MPS METROGYL DG CILACAR TC RANTAC RD
Slide 18: Building Stronger Brand Franchises
Building Stronger Brand Franchises INR 126 crs INR 236 crs INR 83 crs INR 153 crs INR 66 crs INR 104 crs IQVIA MAT Sept’22 IQVIA MAT Sept’25 IQVIA MAT Sept’22 IQVIA MAT Sept’25 IQVIA MAT Sept’22 IQVIA MAT Sept’25 NICARDIA SPORLAC RAZEL BETA-NICARDIA SPORLAC GG RAZEL -F NICARDIA RETARD SPORLAC ART RA
Slide 19: JB Pharma ranks amongst the Top 10 in Cardiac Therapy
JB Pharma ranks amongst the Top 10 in the Cardiac Therapy; 3 brands in top 25 in Cardiology segment #08 MAT Sept’22 MAT Sept’23 MAT Sept’24 MAT Sept’25 #08 4 4 3 3 28 19 16 19 #08 29 22 14 12 #11 #15 3 brands in Top 25 in the Cardiology segment MAT MAT MAT MAT MAT Sept’24 Sept’25 Sept’21 Sept’22 Sep
Slide 20: Good Performance in all Acquired Portfolios
Good Performance in all Acquired Portfolios • Sporlac franchise revenue at INR 153 crores (IQVIA MAT Sept’25) as against INR 83 crores (IQVIA MAT Sept’22), Probiotic growing at CAGR of 23% Portfolio • Lobun growing at 3 years CAGR of 39% and registered strong YoY growth of 35% • Azmarda clocked sale
Slide 21: Sporlac franchise nearly doubles in 3 years
Sporlac franchise nearly doubles in 3 years 129 crores Sporlac Franchise 105 crores 95 crores 23% INR 83 crs INR 153 crs 78 crores IQVIA MAT Sept’22 IQVIA MAT Sept’25 22% 11% SPORLAC GG MAT Sept’22 MAT Sepr’23 MAT Sept’24 MAT Sept’25 SPORLAC ART SPORLAC EVA Sporlac brand is now INR 129 crore (IQVIA
Slide 22: Razel: Another INR 100+ crores growing franchise
Razel: Another INR 100+ crores growing franchise 104 93 73 66 Razel franchise crosses INR 100 crores as per IQVIA MAT Sep’25 data MAT Sept'22 MAT Sept'23 MAT Sept'24 MAT Sept'25 Razel franchise Sales Razel franchise registered YoY growth of 12% as per IQVIA MAT Sept’25 35% 9.2 crores 8.6 crores Raze
Slide 23: Ophthalmology portfolio from Novartis gaining momentum
Ophthalmology portfolio from Novartis gaining momentum post smooth transition After smooth integration in January’24, the 115 ophthalmology portfolio sales is progressing well Portfolio sales grew 10% to INR 115 crs in H1 FY26 vs INR 105 crs in H1 FY25 as per IQVIA data 105 Dedicated field force of
Slide 24: International Business Q2 FY26 vs Q2 FY25
International Business Q2 FY26 vs Q2 FY25 7% 441 413 2% 300 306 20% o International business revenue grew at 7% to INR 441 113 crores vs INR 413 crores 94 16% 19 22 o International formulations business grew by 2% to INR 306 Total International CDMO API crores International Formulations Business • R
Slide 25: Q2 FY26 Financial Performance (Consolidated)
Q2 FY26 Financial Performance (Consolidated) Particulars Q2 FY26 Q1 FY26 Q2 FY25 YoY Growth H1 FY 26 H1 FY 25 YoY Growth Revenue from Operations 1085 1094 1001 8% 2179 2005 9% Cost of Goods Sold 346 347 338 2% 693 678 2% Gross Profit 739 747 662 12% 1486 1327 12% Gross Profit Margins 68.2% 68.3% 66.
Slide 26: Sustainability Report: FY 2024 - 2025
Sustainability Report: FY 2024 - 2025 Reporting Framework: Report prepared in accordance with the GRI 2021 Standards United Nations Sustainable Development Goals (UN SDGs) Reporting Period: This report covers the sustainability performance of the company for the period from 1st April 2024 to 31st Ma
Slide 27: Impact created in FY 2024 - 2025
Impact created in FY 2024 - 2025 Areas Description ESG Report JB Pharma published its Fourth Sustainability Report aligned with the United Nations SDG Goals, GRI Framework. Det Norske Veritas (DNV) has provided Limited level assurance on the Sustainability Report 2024-2025. The assurance ESG Assuran
Slide 28: FY 2024-2025 Sustainability Performance Highlights
FY 2024 -2025 Sustainability Performance Highlights Environment Social Governance • >34% decrease in Scope 1 emissions • Zero cases pertaining to • Conducted Human Rights issues of conflict of interests • 173,185 GJ of our energy derived from renewable sources of Assessment for all internal in case
Slide 29: About JB Pharma
About JB Pharma J.B. Pharma (BSE: 506943 | NSE: JBCHEPHARM | For further information, please ISIN: INE572A01028), established in 1976, is one contact: of the fastest growing pharmaceutical companies in India and a leading player in the hypertension Narayan Saraf, Chief Financial Officer segment. Bes
Slide 30: Thank you
GOOD PEOPLE _for GOOD HEALTH Thank you CF Xin) www.jbpharma.com
J. B. Chemicals & Pharmaceuticals — Q2 FY26 Earnings Presentation on 6ix